Provided by Tiger Fintech (Singapore) Pte. Ltd.

MannKind

5.25
+0.26005.21%
Post-market: 5.24-0.0100-0.19%19:58 EDT
Volume:2.39M
Turnover:12.20M
Market Cap:1.59B
PE:52.50
High:5.26
Open:4.98
Low:4.91
Close:4.99
Loading ...

MannKind Corp - Nintedanib DPI Safe and Well Tolerated in Phase 1 Study

THOMSON REUTERS
·
04 Nov 2024

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

THOMSON REUTERS
·
04 Nov 2024

MannKind Corp - No Serious Adverse Events or Study Drug Discontinuation

THOMSON REUTERS
·
04 Nov 2024

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

Zacks
·
01 Nov 2024

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (Ntm) Lung Disease

THOMSON REUTERS
·
31 Oct 2024

MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...

GuruFocus.com
·
10 Oct 2024

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Zacks
·
09 Oct 2024

Why MannKind (MNKD) Could Beat Earnings Estimates Again

Zacks
·
08 Oct 2024

Exploring High Growth Tech Stocks In The United States October 2024

Simply Wall St.
·
04 Oct 2024

MannKind (MNKD) Just Overtook the 20-Day Moving Average

Zacks
·
04 Oct 2024

MannKind announces 30-week results from Phase 4 INHALE-3 study

TIPRANKS
·
30 Sep 2024

MannKind Corp: Announced Top-Level 30-Week Results From Its Phase 4 Inhale-3 Study

THOMSON REUTERS
·
30 Sep 2024

MannKind Corp: Look Forward to Discussing More Details of 30-Week Study Results at Conferences in 2025

THOMSON REUTERS
·
30 Sep 2024

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish

Insider Monkey
·
21 Sep 2024

MannKind Receives Clearance in Japan for Phase 3 Trial of Clofazimine Inhalation Suspension

MT Newswires Live
·
18 Sep 2024

MannKind Announces Clearance From Pmda to Initiate Phase 3 Clinical Trial (ICON-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (Ntm) Lung Disease

THOMSON REUTERS
·
18 Sep 2024